
    
      If the tumor is HER2neu positive, eligible patients will receive trastuzumab and vinflunine
      intravenously (IV) every 3 weeks.

      If the tumor is HER2neu negative, eligible patients will receive vinflunine intravenously
      (IV) every 3 weeks.

      Patients whose cancer does not grow or decreases in size may continue to receive treatment
      until cancer progression. Evaluation of cancer will be every 9 weeks.
    
  